OptimizeRx (NASDAQ:OPRX) Shares Down 6.1% – Here’s What Happened

OptimizeRx Corp. (NASDAQ:OPRX) fell 6.1% during mid-day trading on Tuesday . The company traded as low as $9.73 and last traded at $10.25. 503,028 shares changed hands during mid-day trading, an increase of 104% from the average session volume of 246,718 shares. The stock had previously closed at $10.92.

Wall Street Analyst Weigh In

OPRX has been the subject of a number of research analyst reports. UBS Group set a $23.00 target price on OptimizeRx in a research report on Friday, October 10th. Citizens Jmp lifted their price objective on OptimizeRx from $23.00 to $24.00 and gave the company a “market outperform” rating in a report on Friday, November 7th. Stephens lowered their price objective on shares of OptimizeRx from $20.00 to $17.00 and set an “equal weight” rating for the company in a research note on Monday, November 17th. JMP Securities raised their target price on shares of OptimizeRx from $20.00 to $23.00 and gave the company a “market outperform” rating in a research report on Friday, October 10th. Finally, Zacks Research lowered shares of OptimizeRx from a “strong-buy” rating to a “hold” rating in a report on Monday, December 15th. Six equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $21.00.

OptimizeRx Stock Performance

The business has a 50-day moving average price of $12.94 and a 200-day moving average price of $15.68. The company has a quick ratio of 3.05, a current ratio of 3.05 and a debt-to-equity ratio of 0.20. The firm has a market capitalization of $191.06 million, a price-to-earnings ratio of 27.30 and a beta of 1.18.

OptimizeRx (NASDAQ:OPRX) last announced its earnings results on Thursday, November 6th. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.17. OptimizeRx had a return on equity of 6.37% and a net margin of 0.03%.The firm had revenue of $26.07 million for the quarter, compared to the consensus estimate of $23.83 million. As a group, sell-side analysts forecast that OptimizeRx Corp. will post -0.33 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Calamos Advisors LLC lifted its stake in shares of OptimizeRx by 26.1% during the fourth quarter. Calamos Advisors LLC now owns 97,118 shares of the company’s stock worth $1,191,000 after buying an additional 20,116 shares during the period. State of Alaska Department of Revenue purchased a new position in OptimizeRx in the 4th quarter worth $62,000. Harbor Capital Advisors Inc. lifted its position in OptimizeRx by 12.2% during the 4th quarter. Harbor Capital Advisors Inc. now owns 24,876 shares of the company’s stock worth $305,000 after acquiring an additional 2,708 shares during the period. Harvest Investment Services LLC purchased a new stake in OptimizeRx during the 3rd quarter valued at about $3,441,000. Finally, Worth Venture Partners LLC purchased a new stake in OptimizeRx during the 3rd quarter valued at about $220,000. Hedge funds and other institutional investors own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.